Top Page
Beijing Airdoc Technology Co. Ltd. Class H
(2251)
Beijing Airdoc Technology Co. Ltd. Class H (2251) vs. iShares MSCI Hong Kong ETF (EWH)
Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model
Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 156.37M | 203.96M | 113.66M | 115.18M | 47.67M |
| Gross Profit | 86.68M | 125.13M | 55.85M | 70.24M | 29.09M |
| EBITDA | -259.70M | -113.36M | -159.64M | -126.73M | -49.42M |
| Net Income | -255.46M | -132.53M | -187.23M | -136.99M | -79.63M |
Balance Sheet | |||||
| Total Assets | 1.41B | 1.68B | 1.74B | 1.89B | 435.75M |
| Cash, Cash Equivalents and Short-Term Investments | 774.82M | 1.14B | 1.41B | 1.78B | 374.70M |
| Total Debt | 31.88M | 9.37M | 8.01M | 8.20M | 519.00K |
| Total Liabilities | 134.86M | 127.13M | 68.59M | 74.19M | 27.30M |
| Stockholders Equity | 1.27B | 1.54B | 1.67B | 1.82B | 408.21M |
Cash Flow | |||||
| Free Cash Flow | -167.51M | 8.02M | -392.55M | -140.11M | -64.77M |
| Operating Cash Flow | -165.43M | 23.37M | -380.44M | -112.09M | -42.86M |
| Investing Cash Flow | -11.34M | -385.14M | -154.43M | -22.01M | 91.69M |
| Financing Cash Flow | -33.31M | -18.53M | -17.14M | 1.55B | 240.63M |
Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis
Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.21B | 10.17 | 8.35% | 2.92% | 0.61% | -15.89% | |
60 Neutral | HK$17.39B | 5.75 | -7.44% | 3.10% | 11.55% | -28.15% | |
58 Neutral | HK$4.19B | ― | -75.64% | ― | 42.21% | 29.52% | |
53 Neutral | HK$1.45B | ― | -18.19% | ― | -24.50% | -93.44% | |
53 Neutral | HK$2.89B | ― | -48.48% | 0.43% | -21.82% | -700.17% | |
52 Neutral | HK$2.26B | 33.92 | -7.51% | 1.11% | -0.56% | -323.09% | |
45 Neutral | HK$5.95B | ― | -2.97% | ― | 11.00% | 56.87% |
Beijing Airdoc Technology Co. Ltd. Class H Corporate Events
Beijing Airdoc Technology Co., Ltd. announced the resignation of Dr. HE Chao as an executive Director, effective July 29, 2025, to focus on personal commitments. The company also made changes to its board committees, appointing Dr. HUANG Yanlin as the chairman of the Nomination Committee and Ms. WANG Lin as a member, while Mr. QIN Yong joined the ESG Committee. These changes reflect the company’s ongoing adjustments to its governance structure.
Beijing Airdoc Technology Co., Ltd. has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement provides clarity on the leadership structure and committee memberships, which are crucial for the company’s governance and strategic direction.
Beijing Airdoc Technology Co., Ltd. announced that all resolutions proposed at its 2024 annual general meeting were duly passed by shareholders. The meeting was conducted in compliance with relevant legal and regulatory requirements, with all directors and supervisors in attendance, either physically or via telecommunication. The successful passing of resolutions indicates a smooth operational and governance process, potentially reinforcing stakeholder confidence in the company’s management and strategic direction.
Beijing Airdoc Technology Co., Ltd. has announced the composition of its board of directors and their roles within various committees. This update reflects the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive edge and ensuring sustainable growth in the rapidly evolving medical technology industry.
Beijing Airdoc Technology Co., Ltd. announced the completion of its 2024 H Share Full Circulation, converting 50,151,012 Unlisted Shares into H Shares, which will be listed on the Stock Exchange of Hong Kong. This move marks a significant step in the company’s market operations, potentially enhancing its liquidity and accessibility for investors, thereby strengthening its position in the market.
Beijing Airdoc Technology Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 27, 2025, where shareholders will consider various resolutions. These include approving the company’s 2024 reports, financial accounts, profit distribution plan, and the re-appointment of Ernst & Young as auditors. Additionally, the AGM will address the appointment of Mr. WEI Yubo as an executive director and the use of idle funds for cash management. Special resolutions will cover mandates for issuing new shares and repurchasing H shares. These resolutions are crucial for the company’s strategic financial management and governance, potentially impacting its market positioning and shareholder value.
Beijing Airdoc Technology Co., Ltd. has received approval from the Stock Exchange for the listing and conversion of 50,151,012 H Shares as part of its 2024 H Share Full Circulation initiative. This development involves 26 participating shareholders and marks a significant step in the company’s expansion and market presence, potentially enhancing its liquidity and shareholder base.
Beijing Airdoc Technology Co., Ltd. announced the resignation of Mr. Wei Yubo as a supervisor due to an internal transfer within the company. Mr. Wei has been nominated for the position of executive director, pending shareholder approval at the upcoming annual general meeting. Additionally, Ms. Luo Yujie has been elected as an employee representative supervisor and chairman of the Board of Supervisors, bringing her extensive experience in auditing and internal control to the role.